527430 Single-Cell Tumor Metabolism of Immune Checkpoint Inhibitors Determines Optimal Dosing for This Class of Antibody Therapeutics

Ian Nessler1, Cornelius Cilliers1 and Greg Thurber1,2, (1)Chemical Engineering, University of Michigan, Ann Arbor, MI, (2)Biomedical Engineering, University of Michigan, Ann Arbor, MI
See more of this Session: Engineering in Cancer Biology and Therapy I: Signaling
See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division